glycyl-arginyl-glycyl-aspartyl-seryl-proline has been researched along with Experimental Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Downey, L; Guo, H; Kuo, PC; Marroquin, CE | 1 |
| Berdel, WE; Bieker, R; Bremer, C; Kessler, T; Kreuter, M; Mesters, RM; Padró, T; Persigehl, T; Schwöppe, C | 1 |
2 other study(ies) available for glycyl-arginyl-glycyl-aspartyl-seryl-proline and Experimental Neoplasms
| Article | Year |
|---|---|
Osteopontin increases CD44 expression and cell adhesion in RAW 264.7 murine leukemia cells.
Topics: Animals; Anisomycin; Cell Adhesion; Cell Line, Tumor; Hyaluronan Receptors; Leukemia; Mice; Neoplasms, Experimental; Oligopeptides; Osteopontin; RNA, Messenger; Sialoglycoproteins | 2004 |
Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature.
Topics: Animals; Blood Flow Velocity; Endothelium, Vascular; Humans; Immunoenzyme Techniques; Integrin alphaVbeta3; Magnetic Resonance Imaging; Male; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Neovascularization, Pathologic; Oligopeptides; Recombinant Fusion Proteins; Thromboplastin | 2005 |